Abstract:Abstract MAPK pathway activation is a feature of multiple tumor types. Drugging KRAS and BRAF, the two main oncogenic drivers in the MAPK pathway, has proven successful in the clinic. Inhibition of the downstream effectors, MEK and ERK, can also induce tumor regression. Despite this, many tumors are intrinsically resistant to MAPK pathway inhibitors, or acquire resistance under selective pressure to drug treatment. This creates a need for combination treatments to improve clinical responses. A synthetic lethal (SL) interaction between inhibition of the MAPK pathway and blockade of JNK-JUN signaling has recently been described1. Specifically, data from yeast genetics and CRISPR knockout experiments in human cells have identified MAP2K4 as a potential therapeutic target that could be combined with MAPK inhibitors. To date, however, no potent MAP2K4 inhibitors with in vitro and cellular selectivity against key anti-targets have been reported. Here, we describe the development of potent covalent inhibitors of MAP2K4 kinase activity. Biochemical and cell-based assays show that the compound(s) are selective for MAP2K4 versus anti-targets including MAP2K7 and ERK kinases. The combination of MAP2K4 and MEK/ERK inhibitors was effective in cell lines driven by MAPK signaling. These data provide the rationale for further development of MAP2K4 inhibitors to advance our understanding of this novel drug combination. References: 1. Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018; 28:719-29. Citation Format: Mark Wade, Emiliano Tamanini, Mathieu Unbekandt, Nicola Wallis, John Lyons, Joanne Munck, Andrew Woodhead, Patrick Schopf, Jessie Stow, Charlotte East, Mellissa Clark, Jeffrey St. Denis, Puja Pathuri. Targeting MAPK-driven tumors via inhibition of MAP2K4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5902.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Progress in developing MNK inhibitors

MNK1/2 Inhibition Limits Oncogenicity and Metastasis of KIT-mutant Melanoma

Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-D]pyrimidine Scaffold.

Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis

Using Imidazo[2,1-b][1,3,4]thiadiazol Skeleton to Design and Synthesize Novel MNK Inhibitors.

Selective and Effective Suppression of Pancreatic Cancer Through MNK Inhibition.

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth Through Promyelocytic Leukemia Protein.

Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy

Preclinical Activity of MBM-5 in Gastrointestinal Cancer by Inhibiting NEK2 Kinase Activity.

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

Dual Inhibition of Allosteric Mitogen-Activated Protein Kinase (MEK) and Phosphatidylinositol 3-Kinase (PI3K) Oncogenic Targets with a Bifunctional Inhibitor

Pharmacodynamic evaluation of AUM001/tinodasertib, an oral inhibitor of mitogen-activated protein kinase (MAPK)-interacting protein kinase 1, 2 (MNK1/2) in preclinical models and tissues from a Phase 1 clinical study

The Novel Molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl Acetate Inhibits Phosphoinositide 3-Kinase/akt/mammalian Target of Rapamycin Signalling Through JNK Activation in Cancer Cells.

Inhibition of Multiple MKK Signaling Pathway Suppressed Renal Cell Carcinoma Growth and Angiogenesis in Vivo

Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma

BKM120 inhibits malignant rhabdoid tumor of the kidney through induction of apoptosis and G0/G1 phase arrest

Akt is A Therapeutic Target in Myeloproliferative Neoplasms